Cargando…

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

BACKGROUND: Studies on long-term consequences of COVID-19, commonly referred to as post-COVID condition, in patients with inflammatory rheumatic diseases are scarce and inconclusive. Furthermore, classifying patients with inflammatory rheumatic diseases as having post-COVID condition is complicated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boekel, Laura, Atiqi, Sadaf, Leeuw, Maureen, Hooijberg, Femke, Besten, Yaëlle R., Wartena, Rosa, Steenhuis, Maurice, Vogelzang, Erik, Webers, Casper, Boonen, Annelies, Gerritsen, Martijn, Lems, Willem F, Tas, Sander W, van Vollenhoven, Ronald F, Voskuyl, Alexandre E, van der Horst-Bruinsma, Irene, Nurmohamed, Mike, Rispens, Theo, Wolbink, Gertjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292827/ https://www.ncbi.nlm.nih.gov/pubmed/37398978 http://dx.doi.org/10.1016/S2665-9913(23)00127-3

Ejemplares similares

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2021)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic
por: Boekel, L., et al.
Publicado: (2021)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
por: Raadsen, Reinder, et al.
Publicado: (2023)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2022)

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab
por: de Jong, Tamarah D, et al.
Publicado: (2015)

Impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry
por: Webers, Casper, et al.
Publicado: (2022)

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
por: van Vollenhoven, Ronald F, et al.
Publicado: (2023)

A neutrophil signature is strongly associated with increased cardiovascular risk in gout
por: Vedder, Daisy, et al.
Publicado: (2020)

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
por: van Schie, Karin A., et al.
Publicado: (2016)

The effect of anti-inflammatory treatment on depressive symptoms in spondyloarthritis: does the type of drug matter?
por: Webers, Casper, et al.
Publicado: (2022)

Neutrophil activation identifies patients with active polyarticular gout
por: Vedder, D., et al.
Publicado: (2020)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study
por: Webers, Casper, et al.
Publicado: (2019)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Validation and implementation of a patient-reported experience measure for patients with rheumatoid arthritis and spondyloarthritis in the Netherlands
por: Beckers, Esther, et al.
Publicado: (2020)

Treat-to-target in axial spondyloarthritis: an observational study in daily practice
por: Beckers, Esther, et al.
Publicado: (2021)

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Development, usability and acceptability of an integrated eHealth system for spondyloarthritis in the Netherlands (SpA-Net)
por: Webers, Casper, et al.
Publicado: (2019)

A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks
por: den Uyl, Debby, et al.
Publicado: (2014)

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
por: Webers, Casper, et al.
Publicado: (2020)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up
por: Vogelzang, E. H., et al.
Publicado: (2018)

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: van Sijl, Alper M., et al.
Publicado: (2014)

The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patients—The CARDAS Study
por: Baniaamam, Milad, et al.
Publicado: (2021)

Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis
por: Agca, Rabia, et al.
Publicado: (2021)

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
por: Raterman, Hennie G, et al.
Publicado: (2012)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ggevi97i8i1j5j69sordc9i2i